Novartis' Pluvicto is expected to dominate the market for radioligand therapies for prostate cancer, with ...

Meier and coauthors found that topotecan improved progression-free and overall survival compared with treosulfan in patients with recurrent ovarian cancer following platinum and taxane-based therapy.

A new study suggests that consciousness may be rooted in quantum processes, as researchers found that a drug binding to ...

Discover a new trial that has evaluated and personalised treatments for metastatic castration-resistant prostate cancer, ...

Adjuvant use of anthracycline–taxane combination therapy is an accepted strategy in the management of high-risk early-stage breast cancer. However, the introduction of this regimen raises the ...

The recent ESMO 2024 data highlighted significant advancements in immunotherapy. Check out the results from Merck, BMY, ...

In 2021, the FDA criticised MSD for relying on an early endpoint to seek approval for Keytruda in early-stage TNBC.

Naomi Dempsey, MD, discussed developments in the HER2-positive breast cancer space, including personalized approaches, less ...

Reveal Genomics' TNBCDX predicted response rates and risk of relapse for patients on anthracycline-free neoadjuvant therapy in a retrospective validation study.

30 Study participants (16.6%) had visceral disease at baseline, with liver or lung disease in 25 participants (13.8%). 81 Study participants (44.8%) had measurable disease at baseline, and 97 (53.6%) ...

Data suggest that cabozantinib and pembrolizumab can be effective in patients with advanced gastric or gastroesophageal junction cancer whose disease is resistant or refractory to immune checkpoint ...